Eli Lilly and Company (LLY)
| Market Cap | 999.71B +45.2% |
| Revenue (ttm) | 79.67B +49.6% |
| Net Income | 26.71B +93.6% |
| EPS | 29.79 +94.8% |
| Shares Out | 891.36M |
| PE Ratio | 37.73 |
| Forward PE | 27.55 |
| Dividend | $6.92 (0.62%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 938,051 |
| Open | 1,127.61 |
| Previous Close | 1,123.91 |
| Day's Range | 1,121.54 - 1,138.79 |
| 52-Week Range | 712.05 - 1,292.65 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 1,315.04 (+17.25%) |
| Earnings Date | Aug 5, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 30 analysts, the average rating for LLY stock is "Buy." The 12-month stock price target is $1,315.04, which is an increase of 17.25% from the latest price.
News
Eli Lilly Stock (LLY) Falls on Competitor Novartis’ Cholesterol Drug Setback
Cardiovascular disease treatments are potentially lucrative for the pharma industry.
Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
Eli Lilly Stock (LLY) Gets a Bullish Note from JPMorgan Chase
Sales of the company’s weight-loss drugs are accelerating.
Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense
Drugmakers are getting a boost from strong earnings and M&A. But they're also havens in a rocky market.
Aspen sees Mounjaro Africa sales above $124 million in 2027
Aspen Pharmacare expects African sales of Eli Lilly's blockbuster weight-loss and diabetes drug Mounjaro to exceed 2 billion rand ($124 million) in its current financial year, buoyed by surging deman...
Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
INDIANAPOLIS, Sept. 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026.
GLP-1 weight loss drugs effective even at low starter doses
People taking popular GLP-1 obesity drugs who remain on low starter doses will lose some weight but may still experience side effects, although significantly less nausea than those who graduate to h...
600,000 seniors have signed up for obesity drugs under new Medicare program
U.S. Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz said on Monday that 600,000 seniors have signed up to receive GLP-1 weight loss medications in the first two months o...
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals buil...
Trump administration to announce drug pricing deals
U.S. President Donald Trump is expected to announce a new round of drug-pricing agreements on Monday, a White House official said, part of a push to make healthcare more affordable for Americans.
Eli Lilly Stock (LLY) in Focus After $2.88 Billion Acquisition of Merida Biosciences
The pharma giant is strengthening its pipeline of new drugs.
Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock.
Eli Lilly agrees to acquire Merida Biosciences, the developer of autoimmune drugs, marking the latest move to bolster its portfolio through strategic acquisitions.
Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA
Eli Lilly (LLY) and Company announced 52-week results from TOGETHER-PsO and TOGETHER-PsA, two novel open-label Phase 3b clinical trials evaluating the concomitant use of Taltz and Zepbound compared to...
Eli Lilly to Buy Merida Biosciences For Up to $2.875 Billion
Eli Lilly has agreed to pay up to $2.875 billion in cash for biotechnology company Merida Biosciences in a deal that bolsters the drugmaker's immunology portfolio.
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week 36, when statistically superior improvements versus Taltz alone were observed ...
Eli Lilly to buy Merida Biosciences in $2.88 billion deal
Eli Lilly said on Monday it would acquire privately held Merida Biosciences for up to $2.88 billion in cash, expanding its efforts to develop treatments for immunity-related and allergic...
Eli Lilly to acquire Merida Biosciences for $2.88B in cash
Eli Lilly (LLY) and Merida Biosciences announced a definitive agreement for Lilly to acquire Merida. Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the dis...
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
Merida's antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune function Initial Phase 1 data show MER511 achieved r...
US FDA approves Lilly's Mounjaro to reduce cardiovascular risk
Eli Lilly said on Friday the U.S. FDA has approved its diabetes drug Mounjaro to lower the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at high ri...
Eli Lilly announces FDA approval of Mounjaro to reduce cardiovascular risk
Eli Lilly (LLY) and Company announced that the U.S. FDA approved Mounjaro, a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular events, including…
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 diabetes at high risk for these events – in additi...
Eli Lilly Stock (LLY) Pulls Back After Hitting Record High
The stock had rallied after the company’s latest earnings.
White House to announce new drug pricing deals with biotechs, Bloomberg News reports
U.S. President Donald Trump's administration is planning to announce a new round of drug-pricing agreements with midsize biotech companies on Monday, Bloomberg News reported on Wednesday, c...
Eli Lilly Stock (LLY) in Focus as Alzheimer’s Blood Test Gets FDA Approval
The test has already been approved in Europe.